- Tous > Public Health, Innovation, Intellectual Property and Trade > Research and Development (R&D) - Innovation and Financing
- Mots-clés > availability of affordable essential medicines
- Mots-clés > pharmaceutical gaps
- Mots-clés > pharmaceutical industry - incentive for R&D
- Mots-clés > pharmaceutical research - priorities
- Mots-clés > pharmaceutical research and development (R&D)
- Mots-clés > research - cost of drug development
- Mots-clés > research and development
- Mots-clés > research and development - financing
- Mots-clés > research and development - global financing
- Mots-clés > research and innovation
(2016; 56 pages)
Every day, Médecins Sans Frontières staff confront significant gaps in the availability of medical tools to address the health needs of the people we aim to care for, in crisis-affected communities in more than 60 countries. These gaps – which have persisted for as long as MSF has been in operation – contribute to preventable deaths and exacerbate ongoing humanitarian and medical crises.
Filling these gaps with effective, affordable vaccines, diagnostics and treatments that can be used in a range of contexts, including under resourced and unstable places, could save innumerable lives.
In this report, MSF illustrates how our staff and patients around the world are impacted by the way biomedical research and development is predominantly conducted today.
The report also looks at a broad range of policies aimed at changing this dynamic by incentivising the development of medical tools that truly respond to patient and public health needs, and ensuring they are made broadly accessible.